Clinical trial NCT07010965: SAVE-PCI: NyokAssist™ Small-Bore VAD vs. IABP in Elective High-Risk PCI
Official title: SAVE-PCI is a Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of NyokAssist™ , a Small-bore Percutaneous Ventricular Assist Device (pVAD), in Comparison With Intra-aortic Balloon Pump (IABP) in Patients Undergoing Elective High-risk Percutaneous Coronary Intervention (PCI)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: High-Risk PCI
Lead sponsor: magAssist, Inc.
Sponsor class: INDUSTRY
First posted: 2025-06-08
Enrollment: 236
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: SAVE-PCI is a prospective, multi-center, randomized controlled trial evaluating the safety and efficacy of NyokAssist™, a small-bore percutaneous ventricular assist device (pVAD), in comparison with intra-aortic balloon pump (IABP) in patients undergoing elective high-risk percutaneous coronary intervention (PCI).


Eligibility criteria: Inclusion Criteria:

1. Age eligible (18 ≤ Age ≤ 80)
2. Subject is indicated for a non-emergent percutaneous treatment of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft .
3. Patient presence at least one of the following a or b:

   1. Intervention on an unprotected left main coronary artery or intervention on the last patent coronary artery .
   2. Intervention on patient presenting with three-vessel\* disease.

      * Three-vessel disease was defined as the presence at least one sign ficant stenosis ≥ 50% in the left anterior descending artery (LAD) and/or side branch, left circumflex artery (LCX) and/or side branch, and right coronary artery (RCA) and/or side branch. In the case of left coronary artery dominance, a lesion ≥ 50% in the proximal LAD and the LCX qualified as three-vessel disease.
4. Ejection Fraction ≤40% or Coronary rotational atherectomy or According to the assessment of the cardiac team, PCI requires hemodynamic support .
5. Volunteered to participate and Signed Informed Consent and able to cooperate with the whole trial process.

Exclusion Criteria:

1. Acute ST elevation Myocardial Infarction within 24 hours or CK-MB that have not normalized after acute ST elevation Myocardial Infarction.
2. Pre-procedure cardiac arrest within 24 hours of enrollment requiring CPR.
3. Subject is in cardiogenic shock defined as:

   * CI \< 2.2 L/min/m2 and PCWP \> 15 mmH
   * Hypotension (systolic BP \< 90 mmHg for \>30 minutes or the need for supportive measures to maintain a systolic BP of greater than or equal to 90 mmHg) AND end organ hypoperfusion (cool extremities OR \[a urine output of \< 30 mL/hour AND a HR \> 60 BPM\])
4. Mural thrombus in the left ventricle.
5. The presence of aortic valve replacement or mechanical circulatory support device.
6. Subject has mechanical complications of myocardial infarction.
7. Documented presence of severe aortic stenosis.
8. Documented presence of moderate to severe mitral stenosis.
9. Documented presence of severe aortic insufficiency.
10. Severe peripheral arterial obstructive disease that would preclude device placement.
11. Abnormalities of the aorta that would preclude surgery, including aortic aneurysms,aortic dissection and extreme tortuosity or calcifications.
12. Subject with renal failure (creatinine ≥265μmol/L)
13. Subject with liver dysfunction ( liver enzymes and bilirubin levels ≥3x ULN )
14. Subject has uncorrectable abnormal coagulation parameters (platelet count ≤ 75╳109 /L or fibrinogen ≤ 1.50 g/L)
15. History of recent (within 1 month) stroke or TIA .
16. Severe right ventricular dysfunction,such as severe pulmonary hypertension.
17. Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors or contrast media.
18. Subject with documented heparin induced thrombocytopenia.
19. Subject has pregnant or lactating.
20. Participation in the active follow-up phase of another clinical study of an investigational drug or device within 1 month.
21. Investigators consider unsuitable to participate in the trial.

Primary outcomes:
measure: MACCE-free rate
timeFrame: Device Delivery through 30 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital Capital Medical University
city: Changsha
country: China
facility: The Second Xiangya Hospital of Central South University
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
city: Guangzhou
country: China
facility: Nanfang Hospital Southern Medical University
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University School of Medicine
city: Harbin
country: China
facility: The Second Affiliated Hospital of Harbin Medical University
city: Lanzhou
country: China
facility: The First Hospital of Lanzhou University
city: Shanghai
country: China
facility: ZhongShan Hospital Fudan University
city: Taiyuan
country: China
facility: Peking University First Hospital Taiyuan Hospital
city: Xi'an
country: China
facility: The First Affiliated Hospital of Xi'an Jiaotong University
city: Xiamen
country: China
facility: Xiamen Cardiovascular Hospital Xiamen University
city: Yunnan
country: China
facility: Fuwai Yunnan Hospital Chinese Academy of Medical Science
Study officials:
References: